Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 15;40(8):1516–1530. doi: 10.1038/s41388-020-01627-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A FACs analysis and statistics of BMDMs in GL261-Ctrl and GL261-BATF2 subcutaneous tumours after 15 days injection (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). B FACs analysis of GR-1⁺CD11b⁺MDSCs and Ly-6C⁺Gr-1⁺Mo-MDSCs/MDSCs in U251-Ctrl and U251-BATF2 after 15 days injection. C Statistics of CD11b⁺Gr-1⁺ MDSCs in U251-Ctrl and U251-BATF2 after 15 days injection (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). D Statistics of Gr-1⁺Ly-6C⁺ Mo-MDSCs/CD11b⁺Gr1⁺ MDSCs in U251-Ctrl and U251-BATF2 after 15 days injection (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). E FACs analysis of CD11b⁺Gr-1⁺MDSCs and Gr-1⁺Ly-6C⁺Mo-MDSCs/CD11b⁺Gr-1⁺ MDSCs in U87-sh-NC, U87-sh-554 and U87-sh-1068 after 15 days injection. F Statistics of CD11b⁺Gr-1⁺ MDSCs in U87-sh-NC, U87-sh-554 and U87-sh-1068 after 15 days injection (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). G Statistics of Gr-1⁺Ly-6C⁺ Mo-MDSCs/CD11b⁺Gr-1⁺ MDSCs in U87-sh-NC, U87-sh-554 and U87-sh-1068 after 15 days injection (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). H Representative images of immunofluorescent staining with Gr-1 (green), CD11b (red) and DAPI (blue) in U251-Ctrl and U251-BATF2 intracranial tumours. White triangles indicate the MDSCs. Scale bars, 50 μm. I. ELISA detection of MMP-9, MMP2, VEGF in U251-Ctrl and U251-BATF2 intracranial tumours (n = 3, independent experiment, *p < 0.05, **p < 0.01, ***p < 0.001). J Representative images of immunofluorescent staining with MMP-9 (green) and DAPI (blue) in U251-Ctrl and U251-BATF2 intracranial tumours. Scale bars, 50 μm. K Zymogram analysis of U251-Ctrl and U251-BATF2 tumours.